About this project
These projects are aimed to explore the potential role of the gut microbiome in cancer development and how variation in the intestinal microflora may influence health among cancer patients. Exposure measurements include microbiome profiles derived from stool samples from a large study population. We further use exposure to pharmaceutical therapies, including different types of antibiotic treatments, as markers of dysbiosis. Study outcomes include cancer risk, primarily for colorectal cancer, as well as psychological and somatic health after cancer occurrence.
- Fang Fang, Karolinska Institutet
- Lars Engstrand, Karolinska Institutet
- Nele Brusselaers, Karolinska Institutet